Safety of intra-cerebrospinal fluid chemotherapy in onco-haematological patients: a retrospective analysis of 627 interventions.
Intra-cerebrospinal fluid chemotherapy (ICC) is used widely to treat or prevent neoplastic meningitis (NM), although its safety has not been thoroughly assessed. We aimed to analyse the incidence, severity and cause of the adverse reactions provoked by ICC in a cohort of onco-haematological patients. We retrospectively reviewed all the adverse reactions related to ICC procedures performed by the same researcher over a 5-year period. We classified them according to their severity and cause, and examined their association with certain characteristics of the patients and interventions. A total of 627 procedures were performed on 124 patients, in which 59 adverse reactions were documented (9.4 %). Thirty-two (54 %) of these were considered severe and 30 (51 %) were due to the drug itself. NM was associated with a higher incidence of adverse reactions (p = 0.002) and severe adverse reactions (p < 0.001). Adverse reactions were more common (p = 0.028) and more often severe (p = 0.008) when an Ommaya reservoir was used, as opposed to the lumbar puncture procedure. The use of liposomal cytarabine was also associated with a higher incidence of adverse reactions (p < 0.001) and serious adverse reactions (p < 0.001) than immediate-release drugs. Liposomal cytarabine provoked more adverse reactions attributable to the drug when administered by lumbar puncture (p = 0.192), whereas the remaining drugs had higher risk when administered via Ommaya reservoir (p = 0.015). ICC seems a relatively safe procedure. Adverse reactions appear to be more frequent when NM is already present. Lumbar puncture seems to be safer than the Ommaya reservoir, except when liposomal cytarabine is administered.
Department of Neurology, Hospital Rey Juan Carlos, Universidad Rey Juan Carlos, C/Gladiolo s/n, Móstoles, 28933, Madrid, Spain. javier.pardo@hospitalreyjuancarlos.es.
Javier
J
Pardo-Moreno
Department of Preventive Medicine, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos, Universidad Complutense, Madrid, Spain.
Cristina
C
Fernández
Department of Neurology, Hospital Quirón Madrid, Pozuelo de Alarcón, Madrid, Spain.|Department of Neurology, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos, Universidad Complutense, Madrid, Spain.
Rafael
R
Arroyo
Department of Neurosurgery, Hospital Quirón Madrid, Pozuelo de Alarcón, Madrid, Spain.
Carlos
C
Ruiz-Ocaña
Department of Haematology, Hospital Quirón Madrid, Pozuelo de Alarcón, Madrid, Spain.
Concepción
C
Aláez
Department of Neurology, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos, Universidad Complutense, Madrid, Spain.
María-Luz
ML
Cuadrado
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002555:Cerebrospinal Fluid / Q000187:drug effects; D016009:Chi-Square Distribution; D015331:Cohort Studies; D004333:Drug Administration Routes; D005260:Female; D006801:Humans; D007278:Injections, Spinal; D008297:Male; D055756:Meningeal Carcinomatosis / Q000188:drug therapy*; D008577:Meningeal Neoplasms / Q000188:drug therapy*; D008875:Middle Aged; D055815:Young Adult
D000970:Antineoplastic Agents
Adverse reactions; Intra-cerebrospinal fluid chemotherapy; Neoplastic meningitis